{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T21:39:10Z","timestamp":1790026750183,"version":"4.0.1"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T00:00:00Z","timestamp":1705536000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T00:00:00Z","timestamp":1705536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"DOI":"10.1007\/s40620-023-01833-3","type":"journal-article","created":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T06:40:10Z","timestamp":1705560010000},"page":"739-745","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Points of view in nephrology: personalized management of IgA nephropathy, beyond KDIGO"],"prefix":"10.1093","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6921-4811","authenticated-orcid":false,"given":"Hern\u00e1n","family":"Trimarchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando C.","family":"Fervenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanna","family":"Coppo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,18]]},"reference":[{"key":"1833_CR1","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1681\/ASN.V82199","volume":"8","author":"MG Radford Jr","year":"1997","unstructured":"Radford MG Jr, Donadio JV Jr, Bergstralh EJ, Grande JP (1997) Predicting renal outcome in IgA nephropathy. J Am Soc Nephrol 8:199\u2013207","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"1833_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.kint.2021.05.021","volume":"100","author":"Glomerular Diseases Work Group","year":"2021","unstructured":"Glomerular Diseases Work Group (2021) Kidney disease: improving global outcomes (KDIGO) glomerular diseases work group, KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int 100(4):1\u2013276. https:\/\/doi.org\/10.1016\/j.kint.2021.05.021","journal-title":"Kidney Int"},{"issue":"5","key":"1833_CR3","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/ki.2009.243","volume":"76","author":"DC Cattran","year":"2009","unstructured":"Cattran DC, Coppo R, Cook HT, Feehally J, Roberts IS, Troyanov S, Alpers CE, Amore A, Barratt J, Berthoux F, Bonsib S, Bruijn JA, D\u2019Agati V, D\u2019Amico G, Emancipator S, Emma F, Ferrario F, Fervenza FC, Florquin S, Fogo A, Geddes CC, Groene HJ, Haas M, Herzenberg AM, Hill PA, Hogg RJ, Hsu SI, Jennette JC, Joh K, Julian BA, Kawamura T, Lai FM, Leung CB, Li LS, Li PK, Liu ZH, Mackinnon B, Mezzano S, Schena FP, Tomino Y, Walker PD, Wang H, Weening JJ, Yoshikawa N, Zhang H, Working Group of the International IgA Nephropathy Network and the Renal Pathology Society (2009) The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 76(5):534\u2013545. https:\/\/doi.org\/10.1038\/ki.2009.243. (PMID: 19571791)","journal-title":"Kidney Int"},{"issue":"5","key":"1833_CR4","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.kint.2017.02.003","volume":"91","author":"H Trimarchi","year":"2017","unstructured":"Trimarchi H, Barratt J, Cattran DC, Cook HT, Coppo R, Haas M, Liu ZH, Roberts IS, Yuzawa Y, Zhang H, Feehally J (2017) IgAN classification working group of the international IgA nephropathy network and the renal pathology society; Conference Participants. Kidney Int 91(5):1014\u20131021","journal-title":"Kidney Int"},{"issue":"13","key":"1833_CR5","doi-asserted-by":"publisher","first-page":"3569","DOI":"10.3390\/jcm11133569","volume":"11","author":"H Trimarchi","year":"2022","unstructured":"Trimarchi H, Haas M, Coppo R (2022) Crescents and IgA nephropathy: a delicate marriage. J Clin Med 11(13):3569. https:\/\/doi.org\/10.3390\/jcm11133569. (PMID:35806856;PMCID:PMC9267724)","journal-title":"J Clin Med"},{"issue":"9","key":"1833_CR6","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1681\/ASN.2014070697","volume":"26","author":"V Tesar","year":"2015","unstructured":"Tesar V, Troyanov S, Bellur S, Verhave JC, Cook HT, Feehally J, Roberts IS, Cattran D, Coppo R, VALIGA study of the ERA-EDTA Immunonephrology Working Group (2015) Corticosteroids in IgA nephropathy: a retrospective analysis from the VALIGA Study. J Am Soc Nephrol 26(9):2248\u20132258. https:\/\/doi.org\/10.1681\/ASN.2014070697. (PMID: 25677392; PMCID: PMC4552116)","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"1833_CR7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ekir.2021.10.007.PMID:35005318;PMCID:PMC8720825","volume":"7","author":"S Itami","year":"2021","unstructured":"Itami S, Moriyama T, Miyabe Y, Karasawa K, Nitta K (2021) A novel scoring system based on oxford classification indicating steroid therapy use for IgA nephropathy. Kidney Int Rep 7(1):99\u2013107. https:\/\/doi.org\/10.1016\/j.ekir.2021.10.007.PMID:35005318;PMCID:PMC8720825","journal-title":"Kidney Int Rep"},{"issue":"6","key":"1833_CR8","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1093\/ndt\/gfac025","volume":"37","author":"A Cambier","year":"2022","unstructured":"Cambier A, Troyanov S, Tesar V, Coppo R, Validation Study of Oxford Classification (VALIGA) Group (2022) Indication for corticosteroids in IgA nephropathy: validation in the European VALIGA cohort of a treatment score based on the Oxford classification. Nephrol Dial Transplant 37(6):1195\u20131197. https:\/\/doi.org\/10.1093\/ndt\/gfac025. (PMID: 35108391)","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"1833_CR9","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1681\/ASN.2017010108","volume":"28","author":"AM Sevillano","year":"2017","unstructured":"Sevillano AM, Gutierrez E, Yuste C et al (2017) Remission of hematuria improves renal survival in IgA nephropathy. J Am Soc Nephrol 28(10):3089\u20133099. https:\/\/doi.org\/10.1681\/ASN.2017010108","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"1833_CR10","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1681\/ASN.2017060639","volume":"28","author":"R Coppo","year":"2017","unstructured":"Coppo R, Fervenza FC (2017) Persistent Microscopic hematuria as a risk factor for progression of IgA nephropathy: new floodlight on a nearly forgotten biomarker. J Am Soc Nephrol 28(10):2831\u20132834. https:\/\/doi.org\/10.1681\/ASN.2017060639","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"1833_CR11","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1093\/ndt\/gfz267","volume":"36","author":"SA Bobart","year":"2021","unstructured":"Bobart SA, Alexander MP, Shawwa K et al (2021) The association of microhematuria with mesangial hypercellularity, endocapillary hypercellularity, crescent score and renal outcomes in immunoglobulin A nephropathy. Nephrol Dial Transplant 36(5):840\u2013847. https:\/\/doi.org\/10.1093\/ndt\/gfz267","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 2","key":"1833_CR12","doi-asserted-by":"publisher","first-page":"ii19","DOI":"10.1093\/ckj\/sfad232","volume":"16","author":"L Zand","year":"2023","unstructured":"Zand L, Fervenza F (2023) Coppo R Microscopic hematuria as a risk factor for IgAN progression: considering this biomarker in selecting and monitoring patients. Clin Kidney J. 16(Suppl 2):ii19\u2013ii27. https:\/\/doi.org\/10.1093\/ckj\/sfad232","journal-title":"Clin Kidney J."},{"issue":"11","key":"1833_CR13","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1093\/ndt\/gfy338","volume":"34","author":"R Coppo","year":"2019","unstructured":"Coppo R (2019) Towards a personalized treatment for IgA nephropathy considering pathology and pathogenesis. Nephrol Dial Transplant 34(11):1832\u20131838. https:\/\/doi.org\/10.1093\/ndt\/gfy338. (PMID: 30476257)","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"1833_CR14","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1007\/s00467-022-05429-0","volume":"37","author":"H Pottel","year":"2022","unstructured":"Pottel H, Bj\u00f6rk J, Delanaye P, Nyman U (2022) Evaluation of the creatinine-based chronic kidney disease in children (under 25 years) equation in healthy children and adolescents. Pediatr Nephrol 37(9):2213\u20132216. https:\/\/doi.org\/10.1007\/s00467-022-05429-0. (Epub 2022 Jan 24 PMID: 35075492)","journal-title":"Pediatr Nephrol"},{"issue":"9156","key":"1833_CR15","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/s0140-6736(98)03563-6","volume":"353","author":"C Pozzi","year":"1999","unstructured":"Pozzi C, Bolasco PG, Fogazzi GB, Andrulli S, Altieri P, Ponticelli C, Locatelli F (1999) Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet 353(9156):883\u2013887. https:\/\/doi.org\/10.1016\/s0140-6736(98)03563-6. (PMID: 10093981)","journal-title":"Lancet"},{"issue":"1","key":"1833_CR16","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.kint.2016.09.029","volume":"91","author":"SS Bellur","year":"2017","unstructured":"Bellur SS, Lepeytre F, Vorobyeva O, Troyanov S, Cook HT, Roberts IS, International IgA Nephropathy Working Group (2017) Evidence from the Oxford Classification cohort supports the clinical value of subclassification of focal segmental glomerulosclerosis in IgA nephropathy. Kidney Int 91(1):235\u2013243. https:\/\/doi.org\/10.1016\/j.kint.2016.09.029. (PMID: 27914703)","journal-title":"Kidney Int"},{"issue":"8","key":"1833_CR17","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1093\/ndt\/gfy413","volume":"34","author":"H Trimarchi","year":"2019","unstructured":"Trimarchi H, Coppo R (2019) Podocytopathy in the mesangial proliferative immunoglobulin A nephropathy: new insights into the mechanisms of damage and progression. Nephrol Dial Transplant 34(8):1280\u20131285. https:\/\/doi.org\/10.1093\/ndt\/gfy413. (PMID: 30698804)","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"1833_CR18","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1007\/s00467-019-04414-4","volume":"35","author":"H Trimarchi","year":"2020","unstructured":"Trimarchi H, Coppo R (2020) The implications of focal segmental glomerulosclerosis in children with IgA nephropathy. Pediatr Nephrol 35(11):2043\u20132047. https:\/\/doi.org\/10.1007\/s00467-019-04414-4. (Epub 2019 Nov 26 PMID: 31773265)","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"1833_CR19","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s40620-020-00725-0","volume":"33","author":"R Coppo","year":"2020","unstructured":"Coppo R, Robert T (2020) IgA nephropathy in children and in adults: two separate entities or the same disease? J Nephrol 33(6):1219\u20131229. https:\/\/doi.org\/10.1007\/s40620-020-00725-0. (Epub 2020 Apr 20 PMID: 32314305)","journal-title":"J Nephrol"},{"issue":"4","key":"1833_CR20","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.ekir.2018.03.013","volume":"3","author":"A Cambier","year":"2018","unstructured":"Cambier A, Rabant M, Peuchmaur M, Hertig A, Deschenes G, Couchoud C, Kolko A, Salomon R, Hogan J, Robert T (2018) Immunosuppressive treatment in children with IgA nephropathy and the clinical value of podocytopathic features. Kidney Int Rep 3(4):916\u2013925. https:\/\/doi.org\/10.1016\/j.ekir.2018.03.013. (PMID:29988999;PMCID:PMC6035143)","journal-title":"Kidney Int Rep"},{"key":"1833_CR21","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","volume":"373","author":"T Rauen","year":"2015","unstructured":"Rauen T, Eitner F, Fitzner C, Sommerer C, Zeier M, Otte B et al (2015) Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med 373:2225\u20132236","journal-title":"N Engl J Med"},{"key":"1833_CR22","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1001\/jama.2022.5368","volume":"327","author":"J Lv","year":"2022","unstructured":"Lv J, Wong MG, Hladunewich MA, Jha V, Hooi LS, Monaghan H et al (2022) Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the testing randomized clinical trial. JAMA 327:1888\u20131898","journal-title":"JAMA"},{"key":"1833_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01554-4","author":"R Lafayette","year":"2023","unstructured":"Lafayette R, Kristensen J, Stone A, Floege J, Tesa\u0159 V, Trimarchi H, Zhang H, Eren N, Paliege A, Reich HN, Rovin BH, Barratt J, NefIgArd trial investigators (2023) Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial. The Lancet. https:\/\/doi.org\/10.1016\/S0140-6736(23)01554-4. (PMID: 37591292)","journal-title":"The Lancet"},{"key":"1833_CR24","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.54054","volume":"6","author":"FF Hou","year":"2023","unstructured":"Hou FF, Xie D, Wang J, Xu X, Yang X, Ai J et al (2023) Effectiveness of for mycophenolate mofetil among patients with progressive IgA nephropathy: a randomized clinical trial. JAMA Netw Open 6:e2254054","journal-title":"JAMA Netw Open"},{"issue":"4","key":"1833_CR25","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1093\/ckj\/sfab244","volume":"15","author":"A Huerta","year":"2021","unstructured":"Huerta A, M\u00e9rida E, Medina L, Fernandez M, Gutierrez E, Hernandez E, L\u00f3pez-S\u00e1nchez P, Sevillano A, Portol\u00e9s J, Trimarchi H, Praga M (2021) Corticosteroids and mycophenolic acid analogues in immunoglobulin A nephropathy with progressive decline in kidney function. Clin Kidney J 15(4):771\u2013777","journal-title":"Clin Kidney J"},{"key":"1833_CR26","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1053\/j.ajkd.2016.11.027","volume":"69","author":"J-H Hou","year":"2017","unstructured":"Hou J-H, Le W-B, Chen N, Wang W-M, Liu Z-S, Liu D et al (2017) Mycophenolate mofetil combined with prednisone versus full-dose prednisone in IgA nephropathy with active proliferative lesions: a randomized controlled trial. Am J Kidney Dis 69:788\u2013795","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"1833_CR27","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ekir.2023.10.015","volume":"9","author":"J Miao","year":"2023","unstructured":"Miao J, Duriseti P, Radhakrishnan Y, Vaughan L, Fervenza FC, Zand L (2023) Mycophenolate mofetil and steroid for treatment of patients with IgA nephropathy. Kidney Int Rep 9(1):182\u2013185. https:\/\/doi.org\/10.1016\/j.ekir.2023.10.015","journal-title":"Kidney Int Rep"},{"issue":"9","key":"1833_CR28","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.2215\/CJN.0000000000000215","volume":"18","author":"H Zhao","year":"2023","unstructured":"Zhao H, Li Y, Sun J, Xu G, Wang C, Zhou S et al (2023) Immunosuppression versus supportive care on kidney outcomes in IgA nephropathy in the real-world setting. Clin J Am Soc Nephrol 18(9):1186\u20131194","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"1833_CR29","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1093\/ndt\/gfh974","volume":"20","author":"G Frisch","year":"2005","unstructured":"Frisch G, Lin J, Rosenstock J, Markowitz G, D\u2019Agati V, Radhakrishnan J, Preddie D, Crew J, Valeri A, Appel G (2005) Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial. Nephrol Dial Transplant 20(10):2139\u20132145","journal-title":"Nephrol Dial Transplant"},{"key":"1833_CR30","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF et al (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383:1436\u20131446","journal-title":"N Engl J Med"},{"key":"1833_CR31","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"WG Herrington","year":"2023","unstructured":"Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, The EMPA-KIDNEY Collaborative Group et al (2023) Empagliflozin in patients with chronic kidney disease. N Engl J Med 388:117\u2013127","journal-title":"N Engl J Med"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-023-01833-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-023-01833-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-023-01833-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:53:43Z","timestamp":1777564423000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/37\/3\/739\/8306635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,18]]},"references-count":31,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["1833"],"URL":"https:\/\/doi.org\/10.1007\/s40620-023-01833-3","relation":{},"ISSN":["1724-6059"],"issn-type":[{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,18]]},"assertion":[{"value":"1 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"Informed consent obtained from the respective institutions.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}